Liu Mingyue, Lu Zhaoming, Zheng Yan, Cui Yao, Wang Jiazhen, Hou Guiqin
Department of Oncology, People's Hospital of Henan Province, Zhengzhou 450003, China.
Email:
Zhonghua Zhong Liu Za Zhi. 2015 Dec;37(12):885-9.
To explore the differences in sensitivity to rapamycin of five esophageal squamous cell carcinoma cell lines with different differentiation and the changes of sensitivity of the cells after siRNA-interfered expression of p70S6K.
Effects of rapamycin on proliferation of ESCC cell lines with different differentiation, EC9706, TE-1, Eca109, KYSE790 and KYSE450 cells, were investigated using cell counting kit 8 (CCK-8) assay, and according to the above results, the EC9706 cells non-sensitive to rapamycin were chosen to be transfected with p70S6K-siRNA. The changes in sensitivity of cells to rapamycin were measured in vitro and in vivo using CCK-8 kit, flow cytometry and tumor formation in nude mice.
CCK-8 results showed that all the five cell line cells were sensitive to low concentration of rapamycin (<100 nmol/L), but TE-1 and EC9706 cells, which were with poor differentiation, showed resistance to high concentration of rapamycin. After EC9706 cells were treated with 50, 100, 200, 500 and 1 000 nmol/L rapamycin and p70S6K-siRNA, the proliferation rates of EC9706 cells were (48.67 ± 1.68)%, (15.45 ± 1.54)%, (14.00 ± 0.91)%, (10.97 ± 0.72)% and (2.70 ± 0.32)%, respectively, and were significantly lower than that of cells treated with 50, 100, 200, 500 and 1 000 nmol/L rapamycin and control siRNA [(74.53 ± 1.71)%, (68.27 ± 1.35)%, (71.74 ± 2.44)%, (76.23 ± 1.02)% and (80.21 ± 2.77)%] (P<0.05 for all). The results of flow cytometry showed that the ratios of cells in G1 phase of the p70S6K-siRNA, rapamycin and p70S6K-siRNA+ rapamycin groups were (53.82 ± 1.78)%, (57.87 ± 4.01)% and (73.73 ± 3.68)%, respectively, significantly higher than that in the control group (46.09 ± 2.31)% (P<0.05 for all). The results of tumor formation test in vivo showed that the inhibitory effect of rapamycin on tumor growth was stronger after the cells were transfected with p70S6K-siRNA, and the inhibition rate was 96.5%.
ESCC cells with different differentiation have different sensitivity to rapamycin, and p70S6K-siRNA can improve the sensitivity of cells to rapamycin in vitro and in vivo.
探讨5种不同分化程度的食管鳞状细胞癌细胞系对雷帕霉素敏感性的差异以及小干扰RNA(siRNA)干扰p70S6K表达后细胞敏感性的变化。
采用细胞计数试剂盒8(CCK-8)法检测雷帕霉素对不同分化程度的食管鳞状细胞癌细胞系EC9706、TE-1、Eca109、KYSE790和KYSE450细胞增殖的影响,根据上述结果,选择对雷帕霉素不敏感的EC9706细胞转染p70S6K-siRNA。采用CCK-8试剂盒、流式细胞术及裸鼠成瘤实验检测细胞对雷帕霉素敏感性的变化。
CCK-8结果显示,5种细胞系细胞均对低浓度雷帕霉素(<100 nmol/L)敏感,但分化程度差的TE-1和EC9706细胞对高浓度雷帕霉素耐药。EC9706细胞分别用50、100、200、500和1 000 nmol/L雷帕霉素及p70S6K-siRNA处理后,细胞增殖率分别为(48.67±1.68)%、(15.45±1.54)%、(14.00±0.91)%、(10.97±0.72)%和(2.70±0.32)%,均显著低于用50、100、200、500和1 000 nmol/L雷帕霉素及对照siRNA处理的细胞[(74.53±1.71)%、(68.27±1.35)%、(71.74±2.44)%、(76.23±1.02)%和(80.21±2.77)%](均P<0.05)。流式细胞术结果显示,p70S6K-siRNA组、雷帕霉素组及p70S6K-siRNA+雷帕霉素组G1期细胞比例分别为(53.82±1.78)%、(57.87±4.01)%和(73.73±3.68)%,均显著高于对照组(46.09±2.31)%(均P<0.05)。体内成瘤实验结果显示,细胞转染p70S6K-siRNA后雷帕霉素对肿瘤生长的抑制作用增强,抑制率为96.5%。
不同分化程度的食管鳞状细胞癌细胞对雷帕霉素敏感性不同,p70S6K-siRNA可提高细胞在体内外对雷帕霉素的敏感性。